Helvetesild i et samfunnsperspektiv

Report number: OE-rapport 2023-26
Title: Helvetesild i et samfunnsperspektiv
Client: GSK
Published: June 23
Link: PDF

Revidert versjon publisert oktober 2023. I revidert versjon er det spesifisert at anslagene som presenteres for forekomst er årlige insidensrater.

See all publications

Newest articles

Alternative clinical endpoints: The path to better treatment?

On November 27, Oslo Economics and Bristol Myers Squibb are hosting a breakfast meeting on the healthcare system’s structure and its ability to prioritize in today’s rapidly evolving technological landscape.
Join us to hear presentations from a range of engaging speakers and participate in the discussion.

Collaboration on green development projects – possible effects and gains: Oslo Economics receives research funding from the Norwegian Competition Authority

Oslo Economics has received research funding from the Norwegian Competition Authority for the implementation of the project “Cooperation on green development projects – possible effects and gains”.

Supreme Court to decide whether a municipal capital injection to a commercial gym is unlawful State aid

Last week, a case of importance for state aid law and competition economics was heard in the Supreme Court in Norway.

Helvetesild i et samfunnsperspektiv

Alternative clinical endpoints: The path to better treatment?

Collaboration on green development projects – possible effects and gains: Oslo Economics receives research funding from the Norwegian Competition Authority

Supreme Court to decide whether a municipal capital injection to a commercial gym is unlawful State aid

Bergen

Oslo

Berlin